Tianmin Xu

Dr. Tianmin Xu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
XZXi-Wen Zhang
Xi-Wen Zhang
YWYishi Wu
Yishi Wu
TXTianmin Xu
Tianmin Xu
MCmanhua cui
manhua cui
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.

30 July 2026 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
JHJiaxing He
Jiaxing He
DWDongying Wang
Dongying Wang
MFMeiqi Fu
Meiqi Fu
YWYishi Wu
Yishi Wu
SWShuying Wu
Shuying Wu
TXTianmin Xu
Tianmin Xu
Primary high-risk human papillomavirus (hrHPV) testing improves the sensitivity of cervical cancer screening but requires effective triage to distinguish w

23 March 2026 in Bioorganic Chemistry
Verified
Journal Article
Closed access
DWDongying Wang
Dongying Wang
JHJiaxing He
Jiaxing He
SWShuying Wu
Shuying Wu
SLShanshan Liu
Shanshan Liu
HWHongxin Wang
Hongxin Wang
TXTianmin Xu
Tianmin Xu